Table 2.
Neuropsychological Data for 62 Patients
| Measure, Mean (SD), | Patients in Treatment Group | F | P Value | ||
|---|---|---|---|---|---|
| ANTHR (n = 20) |
Non-ANTHR (n = 19) |
No Chemotherapy (n = 23) |
|||
| HVLT-R | |||||
| Total recall | 50 (6.5) | 55 (11.0) | 57 (5.0) | 3.73 | .03a |
| Delayed recall | 48 (5.8) | 56 (7.5) | 56 (4.9) | 11.11 | <.001a |
| Executive function | 49 (9.2) | 49 (11.8) | 53 (8.6) | 1.56 | .22 |
| Verbal fluency | 53 (10.4) | 53 (8.2) | 57 (8.6) | 0.233 | .79 |
| BRIEF | 60 (12.0) | 59 (9.4) | 49 (8.1) | 7.27 | .002b |
| CAD | 52 (11.0) | 52 (10.0) | 42 (10.0) | 5.64 | .006b |
Abbreviations: ANTHR, anthracycline-based chemotherapy; BRIEF, Behavioral Rating Inventory of Executive Function; CAD, Clinical Assessment of Depression; HVLT-R, Hopkins Verbal Learning Test—Revised.
a
See eFigure in the Supplement for pairwise comparisons.
b
Higher scores on the BRIEF or CAD indicate elevated symptoms, for all other cognitive measures, higher scores indicate better performance.